Galectin-3 and sST2 as Prognosticators for Heart Failure Requiring Extracorporeal Life Support: Jack n’ Jill
Extracorporeal life support provides perfusion for patients with heart failure to allow time for recovery, function as a bridge for patients to heart transplantation, or serve as destination therapy for long term mechanical device support. Several biomarkers have been employed in attempt to predict...
Main Authors: | Jianli Bi, Vidu Garg, Andrew R. Yates |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-01-01
|
Series: | Biomolecules |
Subjects: | |
Online Access: | https://www.mdpi.com/2218-273X/11/2/166 |
Similar Items
-
Impella versus extracorporal life support in cardiogenic shock: a propensity score adjusted analysis
by: Bernhard Wernly, et al.
Published: (2021-04-01) -
Association of Fluid Balance and Survival of Pediatric Patients Treated With Extracorporeal Membrane Oxygenation
by: Prakadeshwari Rajapreyar, et al.
Published: (2021-09-01) -
Overview of Veno-Arterial Extracorporeal Membrane Oxygenation (VA-ECMO) Support for the Management of Cardiogenic Shock
by: Adamantios Tsangaris, et al.
Published: (2021-07-01) -
FIVE-YEAR EXPERIENCE IN PERIPHERAL VENOARTERIAL EXTRACORPOREAL MEMBRANE OXYGENATION AS A METHOD OF MECHANICAL CIRCULATORY SUPPORT IN POTENTIAL HEART TRANSPLANT RECIPIENTS
by: S. V. Gautier, et al.
Published: (2017-01-01) -
Complete recovery of fulminant cytotoxic CD8 T‐cell‐mediated myocarditis after ECMELLA unloading and immunosuppression
by: Ivana Jurcova, et al.
Published: (2020-08-01)